Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Lung Cancer
•
Medical Oncology
•
Non-small cell lung cancer
Would you consider adjuvant immunotherapy for additional 1 year for a Stage III (T3N2) squamous cell lung cancer, PDl-1 50% who had path CR after checkmate neoadjuvant chemo immunotherapy?
Related Questions
How do you approach treatment selection for patients with non-small cell lung cancer who have uncommon EGFR mutations compared to those with common mutations?
Given potential long-term CV toxicity concerns with lorlatinib and data suggesting that dose reduction does not compromise efficacy, do you ever recommend initiating and/or maintaining lower-dose lorlatinib in ALK+ NSCLC?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
How do you approach treatment selection among novel bispecific antibodies and ADCs for patients with EGFR+ NSCLC previously treated with 3rd generation EGFR inhibitors?
When will you select Dato-DXd for patients with EGFR-mutated non-small cell lung cancer?
Does anyone have experience obtaining sunvozertinib in the second-line setting for patients with EGFR exon 20 insertion mutations?
How do you prioritize treatment in a lung cancer patient who has HER2 IHC3+ along with other actionable mutations that have tumor-specific drugs available?
Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?
What are your top takeaways in thoracic cancers from ESMO 2025?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
